-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The oral Janus kinase inhibitor Upadacitinib has been approved to treat rheumatoid arthritis.
Researchers recently launched the SELECT-PsA 1 study to evaluate the efficacy and safety of Upadacitinib treatment in patients with psoriatic arthritis who have not responded to or are intolerant to traditional antirheumatic drug treatments .
Researchers have recently launched the SELECT-PsA 1 study to evaluate the efficacy and safety of Upadacitinib treatment in patients with psoriatic arthritis who have not responded to or are intolerant to traditional antirheumatic drug treatments.
In this 24-week phase III trial, patients were randomized to receive oral Upadacitinib (15 mg or 30 mg once daily), placebo, or subcutaneous adalimumab (40 mg every 2 weeks).
1704 patients participated in the study.
At week 12, the proportion of patients who responded to ACR20 in each group was as follows: 70.
Differences in ACR20 response rates between groups
Studies believe that for patients with psoriatic arthritis, Upadacitinib treatment is better than placebo in terms of ACR20 response at week 12, and the 30mg Upadacitinib treatment group is better than adalimumab .
For patients with psoriatic arthritis, Upadacitinib treatment was better than placebo in terms of ACR20 response at week 12.
Original source:
Iain B.
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
Leave a message here
